Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder

C. N. Sternberg, M. G. Arena, F. Calabresi, P. De Carli, A. Platania, M. Zeuli, D. Giannarelli, A. Cancrini, V. Pansadoro

Research output: Contribution to journalArticle

Abstract

Background. Based on the excellent results with combination chemotherapy such as M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) in patients with advanced disease, neoadjuvant chemotherapy has been advocated to improve survival and in some cases to permit bladder conservation. Methods. A Phase II study of neoadjuvant M-VAC chemotherapy was performed in patients with T2-T4N0M0 bladder tumors. After clinical staging, three cycles of M-VAC were given. After patients underwent postchemotherapy clinical restaging, pathologic restaging (partial or radical cystectomy) was planned. Results. Forty-six patients are evaluable. A clinical response was attained in 78%. Six patients (13%) had stable disease, and four (9%) had progression. After chemotherapy, 17 patients underwent radical cystectomy, none of whom were pTO. In this group, 10 of the 17 (59%) are alive at a median follow-up of 37+ months (range, 8-62+ months). Eleven patients had a partial cystectomy; 7 of the 11 (64%) are alive, 6 (55%) with a preserved bladder. Eighteen patients had clinical restaging only, and did not have pathologic staging. Median follow-up for this group is 36+ months (11-65+ months). Twenty-one of the 29 (72%) patients managed with conservative surgery or transurethral resection of the bladder alone are alive with a functional bladder. Median survival for all patients has not yet been reached. Two-year survival is 82%, and 3-year survival is 70%. Conclusions. The current study is of interest in terms of bladder conservation. Assessment of the true success of any bladder-preserving treatment will require longer follow-up.

Original languageEnglish
Pages (from-to)1975-1982
Number of pages8
JournalCancer
Volume72
Issue number6
Publication statusPublished - 1993

    Fingerprint

Keywords

  • infiltrating transitional cell carcinoma
  • M-VAC
  • neoadjuvant chemotherapy
  • urothelial/bladder cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sternberg, C. N., Arena, M. G., Calabresi, F., De Carli, P., Platania, A., Zeuli, M., Giannarelli, D., Cancrini, A., & Pansadoro, V. (1993). Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Cancer, 72(6), 1975-1982.